Tango Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tango Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-116.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 84% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$18Sales grew 151% in 3 years; of every extra $100 of sales, $18 became extra profit.
Lower than 52% of Healthcare companies in United States.
Asset Productivity Ratio
+151% / -9%In 3 years sales changed by +151% while total assets changed by -9%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-50.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 74% of Healthcare companies in United States.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Tango Therapeutics, Inc. made a loss over the last year. Tango Therapeutics, Inc. owes $0.05 for every $1 it owns. Tango Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTango Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.60The share price is 4.60 times Tango Therapeutics, Inc.'s book value per share, higher than 69% of Healthcare companies in United States.
Market cap
$4.7 BThe total market value of all of Tango Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 83% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.0 BWhat Tango Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.08Net worth divided by the number of shares. The share price of $27.93 is 4.6 times this, which is the P/B above.
Return on equity (ROE)
-21.3%Tango Therapeutics, Inc. lost 21.3% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.05×Tango Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Dividend yield
NoneTango Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+48%Revenue rose 48% in the year to Dec 2025, and grew 36% a year on average over 3 years.
Profit growth
LossTango Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-162.9%Tango Therapeutics, Inc. lost $163 for every $100 of revenue.
Cash vs debt
Net cashTango Therapeutics, Inc. held $310 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tango Therapeutics, Inc.: $4.7 B ÷ $1.0 B (30 Jun 2026) = 4.6.
What is Tango Therapeutics, Inc.'s return on equity?
Tango Therapeutics, Inc. lost 21.3% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does Tango Therapeutics, Inc. owe compared with what it owns?
Tango Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Does Tango Therapeutics, Inc. pay a dividend?
No. Tango Therapeutics, Inc. does not currently pay a dividend.
Is Tango Therapeutics, Inc.'s revenue growing?
Revenue rose 48% in the year to Dec 2025, and grew 36% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.